Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?

Background: in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET), the mTOR inhibitor everolimus is associated with significant improvement in progression-free survival (PFS). This study evaluated the lesional asphericity (ASP) in pretherapeutic somatostatin receptor (SSR) imaging...

Descripción completa

Detalles Bibliográficos
Autores principales: Wetz, Christoph, Rogasch, Julian, Genseke, Philipp, Schatka, Imke, Furth, Christian, Kreissl, Michael, Jann, Henning, Venerito, Marino, Amthauer, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554807/
https://www.ncbi.nlm.nih.gov/pubmed/32971877
http://dx.doi.org/10.3390/diagnostics10090732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554807/
https://www.ncbi.nlm.nih.gov/pubmed/32971877
http://dx.doi.org/10.3390/diagnostics10090732

Ejemplares similares